Clinical trial · Observational
Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases
Displacement and Deformation Analysis of Adaptive Radiotherapy Based on MR-Linac for Large Brain Metastases
NCT06405256CI-TRIAL-00076859unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is an ambispective cohort study to evaluate the displacement and deformation of large brain metastases (BM) treated with magnetic resonance imaging-guided adaptive radiotherapy (MRIgART)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| magnetic resonance imaging-guided adaptive radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- BM patients receiving MRIgART
- description
- For it's an observational study, all patients eligible will be divided into the group "BM patients receiving MRIgART"
- interventionNames
- Radiation: magnetic resonance imaging-guided adaptive radiotherapy
Primary outcomes (1)
- measure
- Intra-cranial progression-free survival (IPFS)
- timeFrame
- From the date of radiation until the date of first documented intracalcarine recurrence or progression, or date of death from any cause, whichever came first, assessed up to 12 months.
- description
- Defined as the time from date of radiation until the date of first documented intracalcarine recurrence or progression, or date of death from any cause, whichever came first.
Secondary outcomes (5)
- measure
- Local control rate (LCR)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years; KPS score ≥ 60. 2. pathologically confirmed lung cancer. 3. diagnosed with brain metastases by enhanced MRI. 4. BM volume ≥ 2cm. 5. Anticipated time to survival\>3 months. 6. Treated with Unity MR-linac. 7. Good compliance; Able to stay still in supine position for 45 minutes and above. Exclusion Criteria: 1. Fail to complete radiotherapy as planned; Anticipated time to survival less than 3 months. 2. Suffer from severe back pain in supine position, unable to receive Unity MR-linac. 3. Suffer from severe claustrophobia. 4. Incomplete pre-Unity image data.
References
Publications (0)
Data not yet available
No reference posted for this study.